AR093825A1 - COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO - Google Patents

COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO

Info

Publication number
AR093825A1
AR093825A1 ARP130104529A ARP130104529A AR093825A1 AR 093825 A1 AR093825 A1 AR 093825A1 AR P130104529 A ARP130104529 A AR P130104529A AR P130104529 A ARP130104529 A AR P130104529A AR 093825 A1 AR093825 A1 AR 093825A1
Authority
AR
Argentina
Prior art keywords
absent
formula
group
alkyl
compounds
Prior art date
Application number
ARP130104529A
Other languages
English (en)
Inventor
Linney Ian
Rancati Fabio
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of AR093825A1 publication Critical patent/AR093825A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0028Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0028Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0065Inhalators with dosage or measuring devices
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/009Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10Preparation of respiratory gases or vapours
    • A61M16/14Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/06Solids
    • A61M2202/064Powder
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms

Abstract

Compuestos que actúan como antagonistas de los receptores muscarínicos a la vez que como agonistas del receptor b2 adrenérgico, composiciones que los comprenden, usos terapéuticos y combinaciones con otros ingredientes farmacéuticamente activos. Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula general (1), donde Q es un grupo de fórmula (2), (3) ó (4); Z es H o OH; Y se selecciona entre Y e Y¹ que son grupos divalentes de fórmula (5) ó (6), respectivamente, donde A¹ y A² en forma independiente están ausentes o son alquileno C₁₋₆; B está ausente o se selecciona entre el grupo que consiste en arileno y heteroarileno, opcionalmente sustituido con uno o más grupos seleccionados entre halógenos, alquilo C₁₋₆, halo-alquilo C₁₋₆ y alcoxi C₁₋₆; C está ausente o es -OC(O)- o es uno de los grupos de fórmula (7) - (9) donde R⁴ es H o alquilo C₁₋₄ lineal o ramificado; D está ausente o se selecciona entre el grupo que consiste en arileno y heteroarileno, opcionalmente sustituido con uno o más grupos alquilo C₁₋₆; n y n son en forma independiente 0 o un entero entre 1 y 3; E está ausente o se selecciona entre -O- y -OC(O)-; G es arileno; R¹ y R² son en forma independiente H o arilo; R³ es un grupo de fórmula (10) u (11), donde R⁵ es un grupo de fórmula (12) donde p es 0 ó 1, P está ausente o es CO, q está ausente o es 1 y W es heteroarilo; y sales farmacéuticamente aceptables o solvatos del mismo.
ARP130104529A 2012-12-06 2013-12-05 COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO AR093825A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12195891 2012-12-06

Publications (1)

Publication Number Publication Date
AR093825A1 true AR093825A1 (es) 2015-06-24

Family

ID=47323975

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104529A AR093825A1 (es) 2012-12-06 2013-12-05 COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO

Country Status (38)

Country Link
US (2) US8987299B2 (es)
EP (2) EP2928889B1 (es)
JP (1) JP6421989B2 (es)
KR (2) KR102156443B1 (es)
CN (1) CN104822678B (es)
AR (1) AR093825A1 (es)
AU (1) AU2013354043C1 (es)
BR (1) BR112015012730B1 (es)
CA (1) CA2893626C (es)
CL (1) CL2015001483A1 (es)
CO (1) CO7400870A2 (es)
CY (2) CY1120159T1 (es)
DK (2) DK2928889T3 (es)
EA (1) EA030552B1 (es)
ES (2) ES2816210T3 (es)
GE (1) GEP20186839B (es)
HK (1) HK1212989A1 (es)
HR (2) HRP20180915T1 (es)
HU (2) HUE037944T2 (es)
IL (1) IL239182B (es)
LT (2) LT3345904T (es)
MA (1) MA38147B1 (es)
MX (1) MX369311B (es)
NZ (1) NZ708738A (es)
PE (1) PE20151216A1 (es)
PH (1) PH12015501247B1 (es)
PL (2) PL3345904T3 (es)
PT (2) PT2928889T (es)
RS (2) RS57232B1 (es)
SA (1) SA515360514B1 (es)
SG (2) SG11201504318UA (es)
SI (2) SI3345904T1 (es)
TN (1) TN2015000244A1 (es)
TR (1) TR201808698T4 (es)
TW (1) TWI637954B (es)
UA (1) UA118181C2 (es)
WO (1) WO2014086924A1 (es)
ZA (1) ZA201503965B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
CN104854105B (zh) * 2012-12-06 2017-05-17 奇斯药制品公司 具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物
MA38147B1 (fr) * 2012-12-06 2018-09-28 Chiesi Farm Spa Composés ayant une activité antagoniste du récepteur muscarinique et agoniste du récepteur bêta2 adrénergique
SG11201504452WA (en) 2012-12-18 2015-07-30 Almirall Sa New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有maba化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β2腎上腺素受體促效劑二者之活性的2-胺基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β2腎上腺素促效劑及M3蕈毒拮抗劑活性之新穎雙環衍生物
TWI703138B (zh) * 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β2腎上腺素受體促效劑活性之化合物
AR104828A1 (es) 2015-06-01 2017-08-16 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
DK3628331T3 (da) * 2015-11-16 2021-09-27 Chiesi Farm Spa Fremgangsmåde til fremstilling af en tørpulverformulering omfattende et antikolinergikum, et corticosteroid og et beta-adrenergikum
EP3383867B1 (en) 2015-12-03 2021-04-14 Chiesi Farmaceutici S.p.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP3484879B1 (en) 2016-07-13 2020-12-30 Chiesi Farmaceutici S.p.A. Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CA2994290C (en) 2017-11-06 2024-01-23 Entech Solution As Method and stimulation sleeve for well completion in a subterranean wellbore

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2222128A (en) 1937-01-29 1940-11-19 Pure Oil Co Preparation and separation of aromatic hydrocarbons
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
JP4490911B2 (ja) 2002-10-11 2010-06-30 ファイザー・インク β−2アゴニストとしてのインドール誘導体
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
CN100569760C (zh) 2003-11-21 2009-12-16 施万制药 具有β2肾上腺素能受体激动剂和毒蕈碱性受体拮抗剂活性的化合物
PL1708992T3 (pl) 2004-01-22 2007-12-31 Pfizer Pochodne sulfonamidów do leczenia chorób
WO2005092861A1 (en) 2004-03-11 2005-10-06 Pfizer Limited Quinolinone derivatives pharmaceutical compositions containing them and their use
US7538141B2 (en) 2004-03-23 2009-05-26 Alan Daniel Brown Compounds for the treatment of diseases
EP1730103B1 (en) 2004-03-23 2010-05-26 Pfizer Limited Formamide derivatives useful as adrenoceptor
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
EP1778626A1 (en) 2004-08-16 2007-05-02 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
EP1833822A2 (en) 2004-08-16 2007-09-19 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
FR2898640B1 (fr) 2006-03-20 2008-04-25 Siemens Vdo Automotive Sas Procede de transmission d'information relatif au fonctionnement d'un moteur a combustion interne
EP2080523A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Compositions comprising an antimuscarinic and a long-acting beta-agonist
SI2599778T1 (sl) 2009-04-23 2017-08-31 Theravance Respiratory Company, Llc Diamidne spojine, ki imajo muskarinski receptor-antagonistično in beta 2 adrenergični receptor-agonistično aktivnost
WO2010126025A1 (ja) * 2009-04-30 2010-11-04 帝人ファーマ株式会社 四級アンモニウム塩化合物
WO2011048409A1 (en) 2009-10-20 2011-04-28 Astrazeneca Ab Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
EP2718281B1 (en) 2011-06-10 2015-09-09 Chiesi Farmaceutici S.p.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
ME02297B (me) * 2011-06-10 2016-02-20 Chiesi Farm Spa Jedinjenja koja imaju aktivnost antagonista muskarinskih receptora i agonist beta2 adrenergičnog receptora
MA38147B1 (fr) * 2012-12-06 2018-09-28 Chiesi Farm Spa Composés ayant une activité antagoniste du récepteur muscarinique et agoniste du récepteur bêta2 adrénergique
CN104854105B (zh) * 2012-12-06 2017-05-17 奇斯药制品公司 具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物

Also Published As

Publication number Publication date
PL2928889T3 (pl) 2018-09-28
TWI637954B (zh) 2018-10-11
TW201427976A (zh) 2014-07-16
TR201808698T4 (tr) 2018-07-23
MX2015006788A (es) 2015-08-05
PT3345904T (pt) 2020-09-07
BR112015012730A2 (pt) 2017-07-11
UA118181C2 (uk) 2018-12-10
MA38147B1 (fr) 2018-09-28
SG10201704032RA (en) 2017-06-29
EP2928889B1 (en) 2018-03-21
US8987299B2 (en) 2015-03-24
IL239182A0 (en) 2015-07-30
CY1120159T1 (el) 2018-12-12
US9371318B2 (en) 2016-06-21
ZA201503965B (en) 2016-09-28
JP2016502557A (ja) 2016-01-28
RS57232B1 (sr) 2018-07-31
SI2928889T1 (en) 2018-05-31
HRP20180915T1 (hr) 2018-07-27
DK2928889T3 (en) 2018-05-22
EA201590873A1 (ru) 2015-09-30
EA030552B1 (ru) 2018-08-31
EP3345904A1 (en) 2018-07-11
CN104822678A (zh) 2015-08-05
KR20150090108A (ko) 2015-08-05
KR20200027049A (ko) 2020-03-11
PE20151216A1 (es) 2015-09-08
GEP20186839B (en) 2018-04-10
ES2670686T3 (es) 2018-05-31
PH12015501247A1 (en) 2015-08-17
NZ708738A (en) 2019-02-22
EP2928889A1 (en) 2015-10-14
PH12015501247B1 (en) 2015-08-17
HUE051394T2 (hu) 2021-03-01
SA515360514B1 (ar) 2016-08-30
SI3345904T1 (sl) 2020-09-30
PT2928889T (pt) 2018-05-29
MA38147A1 (fr) 2018-03-30
AU2013354043B2 (en) 2017-06-15
HRP20201435T1 (hr) 2020-11-27
PL3345904T3 (pl) 2020-12-14
CA2893626C (en) 2021-08-24
CN104822678B (zh) 2017-03-08
EP3345904B1 (en) 2020-07-29
HK1212989A1 (zh) 2016-06-24
JP6421989B2 (ja) 2018-11-14
TN2015000244A1 (en) 2016-10-03
IL239182B (en) 2018-12-31
DK3345904T3 (da) 2020-08-31
RS60864B1 (sr) 2020-11-30
US20150133491A1 (en) 2015-05-14
SG11201504318UA (en) 2015-07-30
WO2014086924A1 (en) 2014-06-12
KR102156443B1 (ko) 2020-09-17
LT2928889T (lt) 2018-06-11
KR102240459B1 (ko) 2021-04-16
HUE037944T2 (hu) 2018-09-28
CO7400870A2 (es) 2015-09-30
CY1123365T1 (el) 2021-12-31
MX369311B (es) 2019-11-05
ES2816210T3 (es) 2021-03-31
AU2013354043C1 (en) 2017-08-31
US20140161736A1 (en) 2014-06-12
CA2893626A1 (en) 2014-06-12
BR112015012730B1 (pt) 2022-07-05
LT3345904T (lt) 2020-09-25
CL2015001483A1 (es) 2015-10-23

Similar Documents

Publication Publication Date Title
AR093825A1 (es) COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO
AR093832A1 (es) COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO
ES2521596T3 (es) Combinación del compuesto GlyT1 con antipsicóticos
CL2016001287A1 (es) Benzamidas sustituidas y procedimiento para su uso
AR080057A1 (es) Piridinas disustituidas como anticancerigenos
CR20120410A (es) Pirrolidina-2-carboxamidas sustituidas
CU24309B1 (es) Compuestos derivados tienopirimidina y composiciones farmacéuticas que los contienen
EA201590534A1 (ru) Новые бициклические производные
CO6640226A2 (es) 5-fluoro-1h-pirazolipiridinas sustituidas y su uso
AR091271A1 (es) Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa
EA201401054A1 (ru) N-циклиламиды в качестве нематоцидов
EA201590292A1 (ru) Соединения, которые являются sip-модулирующими агентами и/или atx-модулирующими агентами
AR089333A1 (es) Antagonistas del receptor de vanilloides de potencial transitorio 1 (trpv1)
CR20160291A (es) Análogos de cortistatina y síntesis y usos de los mismos
AR086546A1 (es) Derivados de 7h-purin-8(9h)-ona como inhibidores de jak
AR088828A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
AR088829A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
AR083879A1 (es) Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos
EA201490037A1 (ru) Антагонисты trpv4
AR103666A1 (es) COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
AR097932A1 (es) Antagonista del receptor de somatostatina del subtipo 5 (sstr5)
AR089814A1 (es) Compuestos que modulan la actividad de los proteasomas
AR089753A1 (es) Derivados de amida heterociclicos como antagonistas del receptor p2x7
AR103414A1 (es) Derivados de hidroxialquil-piperazina como moduladores del receptor cxcr3
EA201370149A1 (ru) Антагонисты рецептора

Legal Events

Date Code Title Description
FB Suspension of granting procedure